Daily brief   for adults 50+ Subscribe AM & PM email
50 Plus HubEverything for Everyone 50+
Customize My age is in the: 50s 60s 70s 80+ Text size
‹ Back to Breaking News
health50+

Medicare $50 GLP-1 Bridge excludes patients already covered for diabetes or sleep apnea

Sunday, August 30, 2026 · 2 sources

Medicare's new GLP-1 Bridge pilot can cut the monthly price of some weight-loss drugs to $50 for certain Part D enrollees. Patients whose FDA-approved conditions already qualify them for Part D coverage, such as Type 2 diabetes or severe sleep apnea, are steered back to their regular plans and higher copays.

WASHINGTON - Medicare's GLP-1 Bridge pilot can drop the monthly cost of some weight-loss drugs to $50 for certain Part D enrollees, NPR and KFF Health News reported. The catch is that many of the sickest patients do not get that price.

Federal law still bars Medicare from covering drugs prescribed solely for weight loss. The 18-month Bridge demonstration, which began in July, is a limited test of covering Wegovy, a KwikPen form of Zepbound, and the oral drug Foundayo for weight management. Eligible people must have Medicare Part D.

Patients with a body mass index of 35 or higher often qualify. Those with a BMI of 27 to 34 can qualify if they also have listed conditions such as prediabetes or cardiovascular disease. Prior authorization for Bridge runs through a CMS contractor, not the Part D insurer, and CMS said many requests are finished in under 12 hours.

The fine print steers a different group away from the $50 price. If the Food and Drug Administration has already approved a GLP-1 for a patient's condition, such as Type 2 diabetes or moderate to severe obstructive sleep apnea, the person is sent back to regular Part D coverage. That path can mean copays of hundreds of dollars a month.

Jeff La Marca, 68, of Basking Ridge, N.J., told NPR he has a BMI of 42, prior heart bypass surgery and prediabetes, yet was denied Bridge because of severe sleep apnea. Primary care physician Taylor Lacy of Roeland Park, Kansas, said the design can leave patients with the greatest medical need paying more.

KFF's Juliette Cubanski estimated about 3.8 million people may qualify for Bridge. If a quarter stay on treatment for the full 18 months, Medicare costs could reach about $3.3 billion; higher uptake would cost more. CMS said thousands of eligible beneficiaries have already filled Bridge prescriptions.

Drugstores report the pilot is catching on among patients who clear the rules. For everyone else, "coverage" still does not mean "affordable." Seniors should ask whether their case is Bridge or standard Part D before counting on a $50 refill.

The 50+ takeaway: Ask your pharmacist whether you are in Bridge or standard Part D. A medical diagnosis that helps justify the drug can also block the $50 price.

Go Deeper

What is the Bridge program?

An 18-month Medicare pilot that can cover certain GLP-1 weight-loss drugs for about $50 a month for qualifying Part D enrollees.

Who can get the $50 price?

Generally people using the drugs for weight loss under Bridge rules, often with BMI 35-plus, or BMI 27-34 with listed conditions, and without an FDA-approved GLP-1 diagnosis that routes them to Part D.

Why were some sick patients denied?

If Part D already covers a GLP-1 for diabetes, sleep apnea or another approved use, Bridge sends them back to their plan's normal cost sharing.

Which drugs are in the pilot?

Wegovy, a KwikPen form of Zepbound, and the oral medication Foundayo, according to NPR's reporting on the CMS demo.

What should you ask the pharmacy?

Whether your prior authorization is Bridge or standard Part D, and what the out-of-pocket price will be before the first fill.